Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

17.23USD
16 Feb 2018
Change (% chg)

$0.17 (+1.03%)
Prev Close
$17.05
Open
$17.15
Day's High
$17.35
Day's Low
$17.10
Volume
131,459
Avg. Vol
352,221
52-wk High
$24.45
52-wk Low
$3.90

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $1,380.17
Shares Outstanding(Mil.): 59.75
Dividend: --
Yield (%): --

Financials

BRIEF-Dynavax Says Heplisav-B Available In U.S. For Prevention Of Hepatitis B In Adults

* DYNAVAX ANNOUNCES HEPLISAV-B™ IS NOW AVAILABLE IN THE UNITED STATES FOR THE PREVENTION OF HEPATITIS B IN ADULTS Source text for Eikon: Further company coverage:

08 Jan 2018

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.

10 Nov 2017

BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults

* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults

10 Nov 2017

BRIEF-Dynavax reports Q3 loss per share $0.38

* Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

03 Nov 2017

BRIEF-Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist

* Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy

19 Oct 2017

Immunotherapy developer Dynavax explores options for Hepatitis B drug - sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

30 Sep 2017

Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

30 Sep 2017

BRIEF-Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

* Dynavax Technologies Corp says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

02 Sep 2017

Competitors

Earnings vs. Estimates